Last reviewed 2026-04-23 · How we verify

MeningitecTM

Meningitec is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroup C polysaccharide capsule.

Meningitec is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroup C polysaccharide capsule. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C.

At a glance

Mechanism of action

The vaccine consists of meningococcal serogroup C polysaccharide conjugated to a protein carrier (tetanus toxoid), which enhances immunogenicity and T-cell dependent immune response. This conjugation allows for improved antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive meningococcal disease caused by serogroup C.

Approved indications

• Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C

Common side effects

• Injection site reactions (pain, redness, swelling)
• Fever
• Myalgia
• Headache
• Fatigue

Key clinical trials

• 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age (PHASE2)
• Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MeningitecTM CI brief — competitive landscape report
• MeningitecTM updates RSS · CI watch RSS
• GlaxoSmithKline portfolio CI